Atara Biotherapeutics and Pierre Fabre Laboratories Publish Data from Phase 3 ALLELE Tab-cel® Trial in The Lancet Oncology” Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, and Pierre…
Field trial results confirm nitrogen-fixing microbial seed treatment products increased yields and reduced fertilizer use in vegetable crops like potatoes -BioConsortia, Inc., a leading agricultural technology company that designs and…
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea…
–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive…
Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scale -Cellular Origins, a TTP Company focused on…
Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), a late-stage botanical biopharmaceutical company focused on the development of a unique portfolio of prescription drugs and cosmeceutical…
a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces that it has received approval of its application…
KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer and 39th indication for KEYTRUDA…
Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance,” or the “Company”), announced today the voting results from the annual meeting of stockholders (the “Meeting”) held today,…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001…
ZELSUVMI™ is expected to be commercially available during the second half of 2024 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™…
a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter,…